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Abstract
Species C human adenovirus serotype 5 (HAdV-C5) is widely used as a vector for cancer gene therapy, because it efficiently
transduces target cells. A variety of HAdV-C5 vectors have been developed and tested in vitro and in vivo for cancer gene
therapy. While clinical trials with HAdV-C5 vectors resulted in effective responses in many cancer patients, administration of
HAdV-C5 vectors to solid tumors showed responses in a limited area. A biological barrier in tumor mass is considered to
hinder viral spread of HAdV-C5 vectors from infected cells. Therefore, efficient virus-spread from an infected tumor cell to
surrounding tumor cells is required for successful cancer gene therapy. In this study, we compared HAdV-C5 to sixteen
other HAdV serotypes selected from species A to G for virus-spread ability in vitro. HAdV-D9 showed better virus-spread
ability than other serotypes, and its viral progeny were efficiently released from infected cells during viral replication.
Although the HAdV-D9 fiber protein contains a binding site for coxsackie B virus and adenovirus receptor (CAR), HAdV-D9
showed expanded tropism for infection due to human CAR (hCAR)-independent attachment to target cells. HAdV-D9
infection effectively killed hCAR-negative cancer cells as well as hCAR-positive cancer cells. These results suggest that HADVD9, with its better virus-spread ability, could have improved therapeutic efficacy in solid tumors compared to HAdV-C5.
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the other hand, oncolytic HAdVs utilizing HAdV-C5 showed
responses in limited area [24–26]. As a biological barrier in tumor
mass hinders virus spread from infected cells [12,27,28], we need
to develop more efficacious oncolytic HAdVs.
A number of transcriptional targeting strategies using tumorspecific promoters have been tried to improve replication
specificity to limit toxicity [29–31]. Numerous infectivity enhancement strategies were tested for targeting cancer cells with no
human coxsackie B virus and adenovirus receptor (hCAR) as a
primary receptor for HAdV-C5 [32,33]. In addition, several
HAdV serotypes were tested to examine antitumor efficacy to solid
tumors by in vivo [34]. Thus, many types of advanced oncolytic
HAdVs have been reported for cancer gene therapy. We need
HAdVs with better virus-spread ability to overcome a biological
barrier in tumor mass. However, strategies to enhance virusspread ability of HAdV-C5 are limited [35,36].
A total of over 50 serotypes of HAdVs, divided into species A to
G, have been identified [37]. These wild type HAdVs produce
different sizes of plaques on cells [38], thus, we hypothesized that
HAdVs with better virus-spread ability can be identified from
alternative serotypes by comparing the size of the plaques. We
examined viral spread ability in vitro of sixteen HAdV serotypes by
plaque assay as compared with that of HAdV-C5. In this study, we
report the biological and physical properties of HAdVs in vitro,

Introduction
Cancer is a major public health problem in the United
States. Approximately 1.64 million new cancer cases and
approximately 580,000 deaths were predicted to occur in the
United States in 2012 [1]. Given this, some local therapies
(surgery and radiation therapy) and systemic therapies (chemotherapy, hormone therapy, and immunotherapy) have greatly
reduced the mortality of cancer disease [1]. However, primary
tumors will often relapse and subsequently metastasize to other
organs [2]. These considerations warrant the development of
new treatment strategies for cancer.
Cancer gene therapy is one feasible treatment that involves
introducing genetic material into human cells to eradicate cancer
[3]. Virotherapy in particular represents a promising new
direction for cancer gene therapy [4,5]. This approach utilizes
viruses designed to specifically kill tumor cells but not normal cells
[6,7]. Because the biology of HAdV-C5 is relatively well
characterized [8], it has emerged as one of the most attractive
candidate virotherapy agents, which are called oncolytic HAdVs
[4]. A number of strategies to specifically kill tumor cells are based
on the interacting molecular mechanisms between adenoviral
biology and cellular signaling pathways associated with human
cancers [5]. A variety of oncolytic HAdVs have been tested in vitro
[9–14] and caused effective responses in clinical trials [15–23]. On
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highlighting HAdV-D9 as a candidate for cancer gene therapy in
solid tumor.

dodecyl sulfate (SDS, Sigma-Aldrich) and proteinase K (SigmaAldrich) at final concentrations of 0.1% (w/v) and 0.1 mg/ml,
respectively. The mixture was incubated at 56uC for 1 hour and
subsequently cooled at room temperature. Purified adenovirus
genome was extracted by a standard method with phenol and
chloroform [43] and dissolved with 100 ml of sterilized H2O. The
titer of the adenovirus genome was calculated on the assumption
that a solution of 50 mg/ml of purified DNA has an absorbance of
1.0 at 260 nm [44]. We then calculated the concentration of the
adenoviral genome using the following formula: adenoviral
genome titer at an absorbance of 1.0 at 260 nm = (5.061025 g/
ml)/molecular mass of the double stranded adenoviral genome6Avogadro’s number (NA) = 6.0261023 mol21 [44]. We summarized accession numbers of the HAdV genomes which were
obtained from GenBank and each genome titer per 1OD at
260 nm in Table S1.

Materials and Methods
Cell Lines
Human embryonic kidney 293 (HEK293), human lung
adenocarcinoma cell line A549, human ovarian adenocarcinoma
cell lines SKOV-3 and OVCAR-3, human pancreatic carcinoma
cell lines BxPC-3 and MIA-PaCa-2, human breast cancer cell lines
AU-565, MCF-7 and ZR-75-1, human malignant mesothelioma
cell lines H2052, H2452 and MSTO-211H, human prostate
cancer cell line PC-3, were obtained from the American Type
Culture Collection (ATCC; Manassas, VA). Human embryonic
kidney 293A was obtained from Life Technologies (Carlsbad, CA,
USA). Chinese hamster ovary (CHO) cells and CHO-hCAR cells
stably expressing human CAR were provided by Jeffrey M.
Bergelson [39]. All cells described above except AU-565, ZR-75-1,
three kinds of malignant mesothelioma cell lines, CHO, and
CHO-hCAR were cultured in Dulbecco’s modified Eagle’s
medium/nutrient mixture F-12 Ham, (DMEM/F12; SigmaAldrich, St. Louis, MO) containing 10% fetal bovine serum
(FBS; Hyclone; Logan, UT), 2 mM L-glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin (Mediatech, Inc., Herndon, VA). The other cell lines were maintained in culture medium
recommended by each supplier. All cells were incubated at 37uC
in an atmosphere of 5% CO2 in air. Also, infected cells were
maintained with medium containing 2% FBS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin.

Measurement of Plaque Sizes
We performed plaque assay as described elsewhere [41] and
measured the sizes of individual single plaques by Traceable
Certificate of Calibration for Digital Caliper (Control Company,
Friendswood, TX, USA). In brief, a solution of purified HAdVs
was subjected to 10-fold serial dilution and A549 cells or 293A
cells were infected with the diluted HAdVs in a six-well plate. After
1 hour post-infection, each solution of HAdVs was removed and
2 ml of fresh DMEM/F12 that contained 2% FBS and 0.75% BD
Difco agar (BD Diagnostic Systems, Sparks, MD, USA) was laid
over infected cells. Subsequently we incubated infected cells and
laid over 2 ml of fresh DMEM/F12 that contained 2% FBS and
0.75% agar at 4 and 8 days post-infection. We culture infected
cells another six days and laid over 2 ml of fresh DMEM/F12 that
contained 2% FBS, 0.75% agar, and 0.033% Neutral red (Life
Technologies, Carlsbad, CA, USA). We measured sizes of 10
individual single plaques which were visualized by neutral red
staining and calculated the mean of plaque sizes. In cases of
HAdV-B16, F40 and F41, we were not able to measure the sizes of
plaques by a caliper due to their very small sizes. Therefore, we
counted the number of plaques produced with these HAdVs on
cells using an inverted IX-70 microscope (Olympus Corporation,
Melville, NY) equipped with a DP71 digital camera (Olympus
Corporation) and software of DP Controller and DP Manager
(Olympus Corporation).

Adenoviruses, Propagation, and Purification
Human adenoviruses (HAdVs), HAdV-C2, B3, E4, C5, D9,
D10, B14, B16, D20, B21, A31, B34, B35, D37, F40, F41, and
D51 were obtained from ATCC and were propagated in A549 or
HEK293 cells. We purified HAdVs in ten T175-cm2 flasks of
infected A549 or infected HEK293 cells by two rounds of cesium
chloride (CsCl) gradient ultracentrifugation [40]. CsCl was
removed by dialysis against phosphate-buffered saline (PBS
[pH 7.4]) containing 10% glycerol. Purified HAdVs were stored
at 280uC prior to experiments.

Titration
Plaque assay was performed to determine the infectious titer
(plaque forming units; PFU/ml) of purified HAdVs on 293A cells
or A549 cells [41]. The particle titer (viral particles [VP]/ml) was
determined by A260 absorbance of purified virus particles and by
assuming that 1.161012 VP/ml has an absorbance of 1.0 at
260 nm [42]. In brief, the particle titer is calculated based on the
protein amount of the purified adenoviruses observed at absorbance at 260 nm under denaturing conditions using SDS (an
OD260 of 1.0 corresponds to 0.28 mg/ml protein in 0.1% [w/v]
SDS buffer). A value of 1.776108 daltons (Da) for the molecular
mass of the VP is obtained by dividing 2.36107 Da (the molecular
mass of adenovirus DNA) by 0.13 because 13% of an adenoviral
particle is DNA. Next, 1.546108 Da, the molecular mass of the
adenoviral proteins that compose the VP, is calculated by
subtracting 2.36107 Da (the molecular mass of the adenovirus
DNA) from 1.776108 Da (the molecular mass of the VP). Finally,
1.161012 particles/ml/OD260 unit is obtained by dividing
2.861024 g/ml protein by 1.546108 Da (the molecular mass of
the adenoviral proteins) and multiplying it with Avogadro’s
number (NA) (6.0261023). In order to calculate the HAdV genome
titer, we extracted the adenovirus genome from purified HAdV. In
brief, 100 ml of purified adenovirus were mixed with sodium
PLOS ONE | www.plosone.org

One-step Growth Curve Analysis of HAdVs
A549 cells were grown to 80% confluence in 6-well plates and
the number of cells was counted to determine a multiplicity of
infection (MOI). Cells were infected with HAdV at an MOI of 10
PFU/cell. Infected cells were maintained in 3 ml of medium
containing 2% FBS and both infected cells and culture medium
were harvested by using a cell scraper at various hours postinfection. We disrupted infected cells along with culture medium
by three cycles of freeze and thaw and removed cell debris by
centrifugation at 1,0006g for 5 minutes (min) at 4uC. The
supernatant was used as the sample of whole HAdV contained in
the fraction of both infected cells and culture medium. Additionally, we separated culture medium and infected cells by
centrifugation at 1,0006g for 5 min at 4uC. The culture medium
was used as a solution of HAdV which was released from infected
cells. The infected cell pellet was resuspended in 2 ml of fresh
medium and disrupted by three cycles of freeze and thaw. The
lysates were centrifuged at 3,5006g for 10 min at 4uC and the
supernatant was used as a sample of HAdV which was held in
infected cells. Solutions of HAdVs prepared from each fraction
were stored at 280uC prior to titration.
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serial PFU/cell. We assessed cytopathic effect induced with HAdV
infection at 6 days post-infection by using CellTiter 96 AQueous
Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison,
WI) in accordance with the manufacture’s instruction. We
measured the absorbance of the formazan product at 490 nm
and the absorbance at 630 nm as a reference by a microplate
reader (PowerWave HT 340, BioTek, Winooski, VT) and
eliminated the value obtained at 630 nm as a background from
that obtained at 490 nm. Cell killing activity induced with the
HAdV infection was represented as relative value to uninfected
cells by using GraphPad Prism 6 (GraphPad Software, Inc, La
Jolla, CA).

Cellular Uptake of HAdV
Cells were grown to 80% confluency in 24-well plate and the
number of cells was counted before viral infection. We infected
cells with HAdV at an MOI of 100 genomes/cell and maintained
infected cells in 1 ml of medium for 30 or 60 min. After 30 or 60
min post-infection, infected cells were harvested and centrifuged
1,0006g for 5 min at 4uC. For a blocking experiment, CHOhCAR cells were grown to 80% confluency in 24-well plate and
removed medium. We incubated CHO-hCAR cells with 1 ml of
FBS-free medium containing recombinant HAdV-C5 fiber knob
protein [45] at a final concentration of 0.5, 5.0 or 50 mg/ml at 4uC
for 1 hour. No blocking agent was added to the control wells. After
1 hour post-incubation, we removed medium and infected cells
with HAdV-C5 or HAdV-D9 at an MOI of 100 genomes/cell for
1 hour. Subsequently, we harvested infected cells and medium,
centrifuged 1,0006g for 5 min at 4uC, and removed supernatant.
Total cell DNA containing adenoviral genome was extracted from
infected cells by a method described previously [46] and stored at
280uC prior to quantitative PCR (qPCR) analysis.

Three-dimensional Cell Viability Assay
We measured cell killing activity of HAdVs in spheroids formed
by Cultrex 3-D Spheroid Colorimetric Proliferation/Viability
Assay (Trevigen, Inc. Gaithersburg, MD). In brief, cells were
seeded at a density of 5.06103 cells per well in a 3-D culture
qualified 96-well spheroid formation plate, centrifuged at 2006g
for 3 minutes at room temperature in a swinging bucket rotor. We
incubated cells at 37uC in an atmosphere of 5% CO2 in air for 72
hours for spheroid formation. We counted cell numbers by
trypsinizing spheroids and infected spheroids with adenovirus at
various MOIs. We assessed cytopathic effect induced with HAdV
infection at 12 days post-infection in accordance with the
manufacture’s instruction. We measured the absorbance of the
formazan product at 560 nm and the absorbance at 630 nm as a
reference by PowerWave HT 340 microplate reader (BioTek) and
eliminated the value obtained at 630 nm as a background from
that obtained at 560 nm. Cell killing activity induced with the
HAdV infection was represented as relative value to uninfected
cells by using GraphPad Prism 6 (GraphPad Software).

Quantitative PCR (qPCR) Analysis
Position 1 refers to the left end of wild-type HAdV-C5 genome
(GenBank accession number AC_000008.1), wild-type HAdV-D9
genome (accession number AJ854486.1). Oligonucleotides corresponding to the sense strand of the HAdV-C5 L4 region (59GAGCGCTCAGGAATCTTGC-39: 25,576–25,594 nucleotide
position [nt]), the antisense strand of the L4 region (59CGCGGTACTTAATGGGCAC-39; 25,645–25,627 nt), the sense
strand of the HAdV-D9 E3 region (59-GTCCCATGGTGACTCTGCT-39: 26,186–26,204 nt), the antisense strand of the
E3 region (59-CAGTGGTCCAGATGCCTCA-39; 26,236–
26,218 nt). The qPCR condition was as follows: 40 cycles of
denaturation at 94uC for 15 seconds (sec) and annealing and
extension at 60uC for 60 sec. Each virus genome extracted from
purified HAdVs was used to generate a standard curve to calculate the
adenoviral L4 or E3 DNA copy number. We calculated a value to
convert one copy number of the HAdV-C5 genome to the copy
number of the HAdV-D9 genome by using the standard curves of
HAdV-genomes (Figure S1). As a result, one copy number of the
HAdV-C5 genome is equivalent to 1.04 of the HAdV-D9. We
normalized cellular uptakes of HAdVs in CHO and CHO-hCAR as a
fold of genome transfer detected in HAdV-C5-infected CHO cells at
1 hour post-infection. Triplicates of analysis were performed with
50 ng of total DNA extracted from infected cells by using SYBR
Select Master Mix (Life Technologies).

Statistical Analysis
The data were expressed as mean+standard deviation (SD) or
mean + standard error of the mean (SEM). Unpaired student t-test
was used for the statistical analysis.

Results
Biological and Physical Properties of HAdVs
We used 16 serotypes (HAdV-C2, B3, E4, D9, D10, B14, B16,
B21, D20, A31, B34, B35, D37, F40, F41, and D51) selected from
species A to G in order to examine virus-spread ability as
compared to HAdV-C5. We summarized cellular receptors for
HAdVs which were suggested due to being experimentally
examined by using some HAdVs in Table S2. We first propagated
HAdVs in a human lung carcinoma cell line, A549 cells, which is a
permissive cell line to propagate HAdVs. Of the tested HAdVs, 10
serotypes (HAdV-C2, B3, E4, D9, D10, A31, B34, B35, D37, and
D51) as well as HAdV-C5 were propagated well in A549 cells, but
6 kinds of HAdVs (HAdV-B14, B16, B21, D20, F40, and F41)
were not. In contrast, these HAdVs (HAdV-B14, B16, B21, D20,
F40, and F41) were propagated well in HEK293 cells (data not
shown). Both A549 and HEK293 cell lines express the tested
HAdVs’ receptors [49], hCAR, human CD46 (hCD46), and avintegrins [49]. Nevertheless, the propagation of 6 kinds of HAdVs
(HAdV-B14, B16, B21, D20, F40, and F41) was restricted in A549
cells. Thus, these experimental observations suggested that 6 kinds
of HAdVs propagated in HEK293 cells had host range diversity
for productive infection. We purified HAdVs which were
propagated in ten T175-cm2 flasks of A549 or HEK293 cells
and measured biological and physical titers of purified HAdVs.
Because 6 serotypes (HAdV-B14, B16, B21, D20, F40, and F41)

Flow Cytometry
Cells were cultured in a 75-cm2 tissue culture flask, harvested
with PBS [pH 7.4] containing 0.53 mM EDTA, and washed with
wash buffer (PBS [pH 7.4] containing 0.1% bovine serum
albumin [BSA]). We incubated 5.06104 cells with anti-human
CAR monoclonal antibody RmcB [47] which was kindly provided
from Dr. Douglas [48] for 1 hour. Following incubation, the cells
were washed three times with wash buffer and incubated with
Alexa Fluor 488-conjugated goat anti-mouse immunoglobulin G
(Invitrogen). After two additional washing steps, the cells were
analyzed using MACSQuant Analyzer (Milteryl Biotec Inc.
Auburn, CA) or Becton Dickinson Fluorescence Activated Cell
Sorter (FACS aria) (BD Biosciences, Franklin Lakes, NJ).

Two-dimensional Cell Viability Assay
Cells were seeded at a density of 5.06103 cells per well in 96well culture plates and infected with adenoviruses at MOIs of
PLOS ONE | www.plosone.org
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infected cancer cells to surrounding cancer cells. Because each
serotype produces different sizes of plaques on monolayer cells
[38], plaque assay is suitable for assessing virus-spread ability
in vitro [36,38,50,51]. We performed plaque assay to identify
HAdVs with better virus-spread ability and summarized the
plaque sizes of HAdVs which were measured by a caliper in
Table 2. HAdV-D9 (mean and standard deviation of the plaque
size; 4.4560.67 mm, n = 10) and HAdV-D51 (mean and standard
deviation of the plaque size; 4.3860.53 mm, n = 10) produced
larger plaques on A549 cells than other serotypes including
HAdV-C5 (Figure 1 and Table 2). Also, we observed clear plaque
morphologies of HAdV-D9 and D51 with larger sizes by
microscopy (Figure S2). On the other hand, the sizes of the
plaques of HAdV-A31, HAdV-B3, B34, B35, D10, D37, and E4
on A549 cells were smaller than those of HAdV-C5 (Figure 1 and
Table 2). As expected, we did not observe the plaques of HAdVF41 on A549 cells (Figure 1). Although we tested plaque assay of
HAdV-F41 at the range of dilution between 5.061024 to
5.061029 on A549 cells, we did not detect any plaques of
HAdV-F41 on A549 cells by microscopy (data not shown). In
contrast to A549 cells, we detected the plaques of HAdV-F41 on
293A cells (Figure S3). Because HAdV-F41 lacked virus-spread
ability on A549 cells, it is not suitable for an oncolytic vector to
solid tumors. Thus, our data demonstrated that HAdV-D9 and
D51 have better virus-spread ability than HAdV-C5. Although
HAdV-D51 as well as HAdV-D9 similarly killed in most cancer
cell lines, cell killing activity by HAdV-D51 was restricted in
pancreatic cell lines, BxPC-3 and MIA-PaCa-2 cells as compared
to HAdV-C5 and D9 (Figure S4). While the nucleotide sequences
for the HAdV-D9 genome as well as the HAdV-C5 genome were
available from GenBank, the HAdV-D51 genome sequence was
not determined yet. Since HAdV-D9 induced cell killing at low
concentrations in broad ranges of cancer cell lines, we selected
HAdV-D9 rather than HAdV-D51. We further analyzed the

were not propagated well in A549 cells, we used 293A cells to
measure those infectious titers by plaque assay. We were able to
count the number of plaques on A549 or 293A cells infected with
most HAdVs by a caliper, but not able to count the plaques of
HAdV-B16, F40, and F41 due to being very small sizes (data not
shown). Therefore, we counted the numbers of plaques of these
HAdVs observed by microscopy (Figures S2 and S3) and then
calculated their infectious titers (Table 1). The infectious titers of
most HAdVs were similar to that of HAdV-C5, but those of
HAdV-B3, HAdV-B16, A31, F40, and F41 were 20- to 890-fold
lower as compared to HAdV-C5 (Table 1). The genome titers of
most HAdVs showed similar values to that of HAdV-C5, and the
ratios of genomes to PFU in HAdVs except HAdV-B3, F40, and
F41 were the range of 10 to 520 (Table 1). Moreover, the values of
particle titers of most HAdVs were similar to that of HAdV-C5,
but the particle titers of HAdV-B16 and F40 showed 10- to 40-fold
lower values than that of HAdV-C5 (Table 1). Thus, the ratios of
particles to PFU in HAdVs except HAdV-A31, B3, F40, and F41
were in the range of 10 to 360 (Table 1). The analyses of the
biological and physical properties of HAdVs purified in this study
were reproducible. Dr. Green et al. have reported that the ratios of
particles to PFU of HAdV-C1 to D30 which were purified from
infected KB cells were the ranges from 11:1 to 2300:1 [38]. Thus,
we obtained similar ratios of particles to PFU in HAdVs except
HAdV-B3 and D21 as compared with data reported by Dr. Green
et al. [38]. Together, our results indicated that some HAdV
serotypes have host range diversity and most HAdVs were
effectively purified from A549 or 293 cells (Table 1).

HAdV-D9 and D51 have Better Virus-spread Ability than
HAdV-C5
In order to develop new oncolytic HAdVs with better virusspread ability than HAdV-C5, we require HAdVs which are
capable of replicating well in tumors and efficiently spreading from

Table 1. Summary of biological and physical titers of wild type HAdVs used in this study.

Host cell line
A549

Species

Total PFUb

PFU/ml
9

8

9

Genomes/ml
11

Genomes/PFU VP/ml

VP/PFU
11

A

31

1.17610 67.64610

3.97610

4.48610

384

2.26610

B1

3

2.83610762.026107

9.636107

1.1461012

40,305

3.7961011

75,800

B2

34

7.17610961.266109

3.5061010

3.9261011

55

4.0961011

57

35

6.00610965.006108

3.0061010

6.9061011

115

1.9061011

32

2

4.17610965.776108

1.0861010

2.2761011

55

1.7861011

43

5

2.536101061.536109

1.0161011

5.1261011

20

1.4661012

58

9

2.336101061.7661010

1.8761011

4.6461012

199

3.5261012

151

10

12

12

357

C

D

293

Serotypesa

9

8

2,513

10

4.83610 62.89610

1.11610

2.49610

514

1.73610

37

2.036101064.166109

7.1261010

1.3761012

67

1.3161012

65

51

9.00610961.006109

6.7561010

2.4961012

277

2.3861012

264

E

4

2.606101062.606109

1.5661011

1.6561012

64

1.4961012

57

B1

16

5.00610865.006108

3.756109

1.4661011

292

3.6061010

72

21

6.006101061.3261010

3.2461011

1.2661012

21

7.6361011

13

B2

14

1.486101066.336109

1.3061011

3.2061012

216

2.2861012

154

D

20

9.336101063.0161010

9.3361011

1.1761012

13

9.7461011

10

F

7

7

40

8.50610 65.63610

41

1.23610864.046107

8

12

2.30610

1.28610

8.266108

7.2061011

15,069

1.00610

11

1,278

5,837

5.0561011

5,504

a

Numbers refer to the serotypes of HAdVs.
Total PFU was calculated with the volume of purified HAdVs.
doi:10.1371/journal.pone.0087342.t001
b
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Figure 1. Plaque morphology of HAdVs on A549 cells. HAdVs (HAdV-C5, D9, D51, E4, and F41) were serially diluted with medium containing
2% FBS and A549 cells were infected with HAdV at the range of dilution of 5.061028 and 5.061029 for 1 hour. We performed plaque assay as
described in the Materials and Methods section. At 14 days post-infection, we stained cells with 2 ml of medium containing 0.75% agar and 0.033%
neutral red in order to visualize individual single plaques on A549 cells. Photographs of plaque morphology of HAdVs were taken with a digital
camera.
doi:10.1371/journal.pone.0087342.g001

HAdV-D9 was efficiently released by an earlier time point from
infected cells to culture medium as compared with HAdV-C5
(Figure 2C). Moreover, the amounts of infectious HAdV-D9 which
were detected in culture medium continued to be significantly
higher than those of infectious HAdV-C5 during viral replication
observed by 12 hours post-infection (Figure 2B and 2C). Thus,
these results demonstrated that the HAdV-D9 progeny were more
efficiently released from infected cells to culture medium as
compared to HAdV-C5.

biological properties of HAdV-D9 with better virus-spread ability
as compared to HAdV-C5.

HAdV-D9 is Efficiently Released from Infected Cells
The plaque sizes of HAdV-D9 on A549 cells were larger than
those of HAdV-C5 (Figure 1 and Table 2). We supposed that the
release of the HAdV-D9 progeny from infected cells is better than
that of HAdV-C5. Therefore, we measured infectious titers of
HAdVs which were released from infected cells to culture medium
at various times post-infection by plaque assay. Also, we
determined infectious titers of HAdVs in infected cells and the
whole of infected cells and culture medium. The replication of
HAdV-D9 illustrated similar kinetics to that of HAdV-C5 in the
whole of both infected cells and culture medium (Figure 2A). Also,
the replication ability of HAdV-D9 in infected cells was
comparable to that of HAdV-C5 (Figure 2B). As expected,

HAdV-D9 Infection is Independent of hCAR
Species D HAdVs are considered to use several cellular
receptors: hCAR, hCD46, av-integrins, and/or sialic acids
[52,53]. Since HAdV-D9 expresses the fiber protein which
contains a binding site for hCAR [54] and is capable of binding
to hCAR [55], it is considered to utilize hCAR as a receptor for
binding to target cells. On the other hand, HAdV-D9 is
considered to possess the ability to interact with target cells
independently of hCAR [53]. In addition, it has been suggested
that the RGD motif of penton-base interacts directly with an
integrin without the association of the fiber and hCAR [56].
Therefore, we examined the modality of HAdV-D9 infection in
CHO and CHO-hCAR cells which stably express full length
hCAR by quantifying the HAdV genomes. One copy number of
the HAdV-C5 genome is equivalent to 1.04 copies of the HAdVD9 genome. HAdV-D9 as well as HAdV-C5 was incorporated
into CHO-hCAR cells (Figure 3A). Of note, the cellular uptake of
the HAdV-D9 genome in CHO cells was approximately 15-fold
higher than that of HAdV-C5 (Figure 3A). Thus, these data
suggested that HAdV-D9 was more efficiently incorporated into
CHO cells as compared to HAdV-C5 (Figure 3A). Also, the
cellular uptake of the HAdV-D9 genome in CHO and CHOhCAR cells was observed in a time-dependent manner (Figure 3B
and 3C). On the other hand, the HAdV-C5 genome was readily
detected in CHO-hCAR cells, but not in CHO cells (Figure 3B
and 3C). Therefore, these results suggested that HAdV-D9
infection to target cells is independent of hCAR. We also
investigated HAdV-D9 binding to CHO-hCAR cells with or
without a blocking of the HAdV-C5 recombinant knob protein.
While the recombinant protein blocked attachment of HAdV-C5
to CHO-hCAR cells in a dose dependent manner, it only partially
inhibited that of HAdV-D9 (Figure 3D). This result was identical
with an observation previously reported in an hCAR-positive
cancer cell line [56]. Thus, the blocking of hCAR mediated by the
HAdV-C5 recombinant knob protein did not inhibit HAdV-D9
infection. Moreover, we assessed whether HAdV-D9 targets
human cancer cells expressing little or no hCAR as well as
hCAR-positive A549 cells. The infection of HAdV-D9 in A549

Table 2. Host cell lines used for viral propagation and plaque
sizes of HAdVs.

Host cell line
A549

Species

Plaque sizeb (mm)

A

31

0.5060.58

B1

3

0.7860.38

B2

34

1.6360.18

C

D

HEK293

Serotypesa

35

1.4560.52

2

2.8661.36

5

2.1960.33

9

4.4560.67

10

0.7360.59

37

1.1360.32

51

4.3860.53

E

4

1.5860.30

B1

16

unmeasurablec

21

4.0660.93

B2

14

1.3560.28

D

20

4.5260.51

F

40

unmeasurablec

41

unmeasurablec

a

Numbers refer to the serotypes of HAdVs.
Plaque sizes of HAdVs were represented as the average of the values obtained
from ten individual single plaques.
c
Plaque sizes of these viruses were not able to be measured by a caliper.
doi:10.1371/journal.pone.0087342.t002
b
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post-infection. We first tested hCAR expression in cancer cell lines
by flow cytometry using anti-hCAR, clone RmcB [58]. A549,
OVCAR-3, BxPC-3, and H2452 cells expressed hCAR at high
levels (Figure 4A). While MIA-PaCa-2 and AU-565 cells expressed
hCAR at middle levels, MCF-7, ZR-75-1, and H2052 cells
expressed hCAR at very low levels [59] (Figure 4A). On the other
hand, hCAR expression in SKOV-3, MSTO-211H, and PC-3
cells was undetectable (Figure 4A). HAdV-D9 was able to induce
cell killing at smaller amounts of infectious viruses in BxPC-3, AU565, MCF-7, ZR-75-1, H2052 and PC-3 as compared to HAdVC5 (Figure 4B). Also, HAdV-D9 as well as HAdV-C5 similarly
killed the other cancer cell lines (Figure 4B). These data
demonstrated that HAdV-D9 infection effectively kills cancer cells
with attenuated hCAR and as well as hCAR-positive. Moreover,
we evaluated cell killing activity of HAdV-D9 in spheroids of A549
or PC-3 cells. HAdV-D9 induced cell killing at smaller amounts of
infectious viruses in PC-3 spheroids as well as A549 spheroids
(Figure 4C), whereas HAdV-C5 showed attenuated cell killing
activity in hCAR-negative spheroids (Figure 4C). Collectively, our
data demonstrated that HAdV-D9 exhibits anticancer efficacy in
broad ranges of cancer cell lines and in an in vitro 3-D model
mimicking solid tumors.

Discussion
A variety of oncolytic HAdVs engineered using HAdV-C5 have
been characterized in vitro and in vivo [9–11]. In particular, 12
kinds of oncolytic HAdVs tested in patients with a variety of
cancers were well tolerated [12,15–23]. Most patients showed
stable disease defined in Response Evaluation Criteria in Solid
Tumor (RECIST) [12,15–23]. On the other hand, intratumoral
administration to solid tumors of an oncolytic HAdV seemed to be
inefficient because tumor sizes in patients were not reduced [24].
To explain the inefficiency, a biological barrier in tumor mass is
considered to hinder viral spread from infected cells [12,27,28].
Adenovirus mutants with improved replication ability and
enhanced virus-spread ability were developed by bioselection
approaches [35,36]. Also, several HAdV serotypes were tested for
identifying new HAdVs with lower seroprevalence and equal or
better antitumor efficacy to solid tumors by in vitro cell killing assay
[34]. Although HAdV-C6 was suggested as a means to address to
solid tumor treatment, it showed anti-cancer activity comparable
to HAdV-C5 [34].
In this study, we focused on virus-spread ability of HAdVs to
overcome a biological barrier in tumor mass. We tested 16
serotypes along with HAdV-C5 in order to examine virus-spread
ability. Ten of 16 serotypes, as well as HAdV-C5, propagated well
in A549 cells (Table 1), but the others did not propagate (data not
shown). Although HAdV-B3 was propagated in A549 cells, it
showed higher values in the ratios of genomes to PFU and VP to
PFU (Table 1). Our data suggested that larger numbers of the
HAdV-B3 particles are needed to produce one plaque as
compared with HAdV-C5. Previous reports demonstrated that
larger amounts of incomplete HAdV-B3 particles are produced in
infected cells [60]. Also, it is difficult to separate incomplete and
infectious virus particles by purification [60]. Thus, purified
HAdV-B3 which we prepared in this study may contain larger
numbers of incomplete viral particles. Moreover, our data showed
that HAdV-B3 and B16 were purified at very low infectious titers
as compared to HAdV-C5 (Table 1). HAdV-B3 and B16 had
attenuated virus-spread ability evidenced by the production of
small plaques (Table 2). On the other hand, species F HAdVs
show host range diversity in cell culture, and it is difficult to
propagate and amplify species F HAdVs [61,62]. Also, we had

Figure 2. Release of HAdV-D9 from infected cells to culture
medium. A549 cells were infected with HAdV-C5 or HAdV-D9 at an
MOI of 10 PFU/cell and harvested at various time points. Samples to
measure the infectious titer of HAdVs were prepared from infected cells
harvested along with culture medium (A), a fraction extracted from
infected cells without culture medium (B), and culture medium (C).
Infectious titers of HAdVs contained in each fraction were measured by
triplicate TCID50 assays. Data points represent mean+standard error of
the mean (n = 3). Unpaired student t-test analysis was performed with
respect to HAdV-C5 at each time point and significance is indicated by
*P,0.05.
doi:10.1371/journal.pone.0087342.g002

cells was approximately 1.3-fold higher than that of HAdV-C5. In
PC-3, AU-565 and MCF-7 cell lines, which express little or no
hCAR [49,57], it was approximately 2- to 4-fold higher than that
of HAdV-C5 (Figure 3E). Thus, HAdV-D9 was incorporated into
not only cancer cell lines which express little or no hCAR but also
hCAR-positive cancer cells (Figure 3E). This data also supported
the concept that the gene transfer mediated by HAdV-D9 is
achieved at an hCAR-independent manner. Taken together,
HAdV-D9 infection demonstrated hCAR-independent tropism in
cancer cells.

HAdV-D9 Exhibits Anticancer Effects in Variety of Cancer
Cell Lines and a Spheroid Model
HAdV-D9 exhibits increased cellular uptake in the absence of
hCAR and demonstrated hCAR-independent tropism in cancer
cells (Figure 3). To examine whether HAdV-D9 infection kills
hCAR-negative cancer cells, we performed in vitro cell killing assay
in a broad range of cancer cell lines including hCAR-positive
cancer cell lines. Cell killing activity of HAdV-D9 in these cell lines
was determined by measuring remaining cell viability at 6 days
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Figure 3. Cellular uptake of HAdV-D9 independently of human CAR. Cells (CHO and CHO-hCAR) were infected with HAdV-C5 or HAdV-D9 at
an MOI of 100 genomes/cell, and total cell DNA extracted from infected cells were used for qPCR analysis. (A) Cellular uptakes of HAdVs in CHO and
CHO-hCAR were represented as a fold of genome transfer in HAdV-C5-infected CHO cells at 1 hour post-infection and normalized by cellular uptake
of HAdV-C5 in CHO cells; HAdV-C5 (black bars) and HAdV-D9 (white bars). (B and C) Cellular uptakes of HAdVs in a time-dependent manner in CHO (B)
and CHO-hCAR (C). Total cell DNA was extracted from infected cells at 0, 30, and 60 min post-infection and used for qPCR analysis; HAdV-C5 (black
squares) and HAdV-D9 (white squares). Data points represent mean+standard error of the mean (n = 3). CHO; human CAR negative CHO cells and
CHO-hCAR; CHO cells stably expressing human CAR. (D) CHO-hCAR cells were treated with the HAdV-C5 fiber knob protein at a final concentration of
0, 0.5, 5.0 or 50 mg/ml at 4uC for 1 hour and then infected with HAdV at an MOI of 100 genomes/cell at 37uC for 1 hour. HAdV-C5 (black bars) and
HAdV-D9 (white bars). (E) Cellular uptakes of HAdV-D9 in cancer cells which express little or no hCAR. Cells were infected with HAdV-C5 or HAdV-D9
at an MOI of 100 genomes/cell for 1 hour post-infection, and total cell DNA extracted from infected cells was analyzed by qPCR. HAdV-C5 (black bars)
and HAdV-D9 (white bars). Cellular uptakes of HAdVs in cell lines were represented as (A) a fold of genome transfer, (B, C and D) a percentage of
genome transfer, and (E) Genome copy numbers per 50 ng of total DNA of each HAdV. Data points represent mean+standard error of the mean
(n = 3).
doi:10.1371/journal.pone.0087342.g003

make oncolytic HAdVs due to abilities of efficient production and
better virus spread in cancer cells. Moreover, a seroprevalence
study in a Belgian population demonstrated that HAdV-D9 and
D51, as well as HAdV-C6, shows low seroprevalence as compared
to HAdV-C5 [63]. These HAdVs may be suitable as gene delivery
vectors for treating patients with pre-existing immunity [63–65].
On the other hand, HAdV-D9 was isolated from stool in 1957
[66], and HAdV-D51 was isolated from a stool specimen of an
AIDS patient with fever, Pneumocystis jirovecii pneumonia, and
diarrhea in 1989 [67]. Recently, HAdV-D9 was suggested to be
associated with acute gastroenteritis in Bangladesh, as it was

difficulty propagating species F HAdVs as well as B14, B16, D20,
and B21 in A549 cells. Collectively, nine serotypes (HAdV-C2, E4,
D9, D10, A31, B34, B35, D37, and D51), as well as HAdV-C5,
were efficiently purified at high infectious titers from infected A549
cells and seemed to merit careful investigation for virus-spread
ability.
We then investigated whether HAdV serotypes have better
ability with regard to virus-spread by comparing plaque morphology with HAdV-C5 and found that HAdV-D9 and D51 generated
larger plaques than those of other serotypes tested (Figure 1 and
Figure S2). HAdV-D9 and D51 were screened as the candidates to
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Figure 4. Analysis of hCAR expression and cell killing activity of HAdV-D9 in cancer cell lines. (A) Analysis of hCAR expression in various
cancer cell lines by flow cytometry. Filled, gray histograms indicate stained cells; open, white histograms indicate unstained control cells. (B) Twodimensional cell viability assay. Cancer cell lines were infected with HAdV-C5 (black squares) or HAdV-D9 (white squares) at indicated MOIs. Cell
survival in each well was measured at 6 days post-infection using an MTS assay and plotted on y-axis as the percentage of the control values obtained
from uninfected cells. (C) Three-dimensional cell viability assay. Spheroids were infected with HAdV-C5 (black squares) or HAdV-D9 (white squares) at
indicated MOIs. Cell survival in each well was measured at 12 days post-infection using an MTT assay and plotted on y-axis as the percentage of the
control values obtained from uninfected cells. Data points represent mean+standard error of the mean (n = 3).
doi:10.1371/journal.pone.0087342.g004

isolated from stools of infants and children with acute gastroenteritis at a frequency of 0.7% (6/917 patients) along with HAdVF40 (0.8% [7/917 patients]) and HAdV-D10 (0.4% [4/917
patients]) [68]. Thus, both viruses seem to be associated with
diarrhea in children and AIDS-patients. However, there are no
serious diseases associated with HAdV-D9, HAdV-D51 nor
HAdV-C5 [69]. Although some serotypes in species D (HAdVD8, D19, and D37) cause epidemic keratoconjunctivitis (EKC) in
humans, HAdV-D9 does not [70,71]. Thus, HAdV-D9 is
considered to be distinct from EKC-associated HAdVs [72].
The pathogenic significance of AIDS-associated HAdV infections,
including HAdV-D51 in AIDS patients is unclear [73–75]. Since
the complete nucleotide sequence of the HAdV-D9 genome, but
not the HAdV-D51 genome, has been available from GenBank,
the HAdV-D9 genome is suitable for characterization of the
biology and vector construction. In addition, HAdV-D51 attenuated cell killing activity in pancreatic cancer cell lines as
compared to HAdV-D9 (Figure S4). Based on these considerations, we characterized the biology of HAdV-D9 identified as a
PLOS ONE | www.plosone.org

candidate of oncolytic HAdV vectors. HAdV-D9 as well as
HAdV-C5 replicated well in A549 cells and the viral progeny was
efficiently released from infected cells as compared to HAdV-C5
(Figure 2). Our results demonstrated that better ability of HAdVD9-spread was correlated with viral release from infected cells to
culture medium (Figures 1 and 2).
HAdVs involved in species D utilize several cellular receptor(s)
which are hCAR, hCD46, integrins, and/or sialic acids for
attachment to target cells [53]. Although several serotypes
involved in species D use sialic acid as a cellular receptor
[76,77], HAdV-D9 does not use it as a receptor [76–78]. The
interaction to hCD46 of HAdV-D9 by comparing species B
HAdVs was not shown [79]. Computational analysis of the
HAdV-D9 genome suggested that the fiber protein contains an
hCAR-binding domain [55]. While HAdV-D9 uses hCAR at low
affinity for attachment as compared to that of HAdV-C5 [55,56],
it is able to attach to av-integrins through its penton-base at fiberindependent manner [56]. Thus, HAdV-D9 is considered to
utilize both hCAR and av-integrins for attachment [56] and
8
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preferentially use av-integrins for attachment [54]. Although
HAdV-D9 binding to hCAR-positive cells was partially blocked by
the HAdV-C5 recombinant knob protein as compared to HAdVC5 (Figure 3D) as previously reported [56], our qPCR analysis of
HAdV binding to CHO cell lines and cancer cell lines with low
hCAR expression demonstrated that HAdV-D9 was capable of
binding to target cells independently of hCAR (Figure 3). Thus, we
obtained a result that HAdV-D9 uses cellular receptor(s) other
than hCAR for attachment.
One of the problems using oncolytic HAdV-C5 vectors is a low
infectivity to hCAR-negative cancer cells [39,80,81]. The hCAR
expression levels tend to be low in the majority of advanced
tumors [82–89]. In addition, the hCAR expression in tumors
exhibits marked distributional heterogeneity [89]. Thus, the varied
and insufficient expression of hCAR hampers uniform HAdV-C5
transduction throughout tumors, especially in advanced tumors.
Therefore, we need to target not only hCAR-positive cancer cells
but also hCAR-negative cancer cells. Since HAdV-D9 efficiently
killed hCAR-negative cancer cell lines as compared to HAdV-C5
(Figure 4), the expanded tropism of HAdV-D9 with better virusspread ability will be useful for treatments of solid tumors. Another
of the problems is that the majority of the HAdV-C5 vectors infect
the liver by coagulation factor X, which is a vitamin K-dependent
coagulation factor and the major factor in hCAR-independent
uptake by hepatocytes, when they are systemically delivered [90].
However, HAdV-D9 does not bind to coagulation factor X [91],
giving HAdV-D9 another advantage as an oncolytic vector over
HAdV-C5, in addition to the better virus spread ability and
expanded tropism of HAdV-D9.
In summary, we have selected HAdV-D9 from 16 serotypes of
HAdV by comparing in vitro virus-spread ability as well as the
in vitro propagation property between a cancer cell line and a cell
line immortalized by the HAdV-C5 E1 gene region. Also, we
revealed that a broad range of cancer cell lines were infected with
HAdV-D9 independently of hCAR status. HAdV-D9 infection
efficiently induced cytopathic effect in 2- and 3-D culture cells. In
this study, we examined HAdV-D9 biology in vitro for a vector
development of cancer gene therapy. Construction of the HAdVD9 vectors is under way in our laboratory in order to overcome
the limitation of HAdV-C5 vector. Our experimental results
provided great impact to the development of HAdV-D9-based
vectors in human gene therapy as well as the elucidation of HAdVD9 biology on the molecular mechanism of its infection.

both plots; HAdV-C5 (black squares) and HAdV-D9 (white
squares). Each data point represents the threshold cycle (Ct)
average of samples prepared in triplicate. One copy number of the
HAdV-C5 genome is equivalent to 1.04 copies of the HAdV-D9
genome.
(TIF)
Figure S2 Comparative analysis of plaque morphology
of HAdVs on A549 cells. Plaque assay was performed as
described in the Materials and Methods section. Monolayers of
A549 cells in a six-well plate were infected with HAdVs, overlaid
with 0.75% agar in growth medium containing 2% FBS, and
stained with 0.033% neutral red at 14 days post-infection. The
pictures showed microscopic view of three individual plaques
formed on A549 cells infected with HAdVs.
(TIF)
Figure S3 Comparative analysis of plaque morphology
of HAdVs on 293A cells. Monolayers of 293A cells in a six-well
plate were infected with HAdVs which were propagated in 293A
cells. After 1 hour post-infection, infected 293A cells were overlaid
with medium containing 0.75% agar and stained with 0.033%
neutral red at 14 days post-infection. The pictures showed
microscopic view of three individual plaques formed on 293A
cells infected with HAdVs.
(TIF)
Figure S4 Cell killing activity of HAdV-D9 and D51 in
cancer cell lines. Nine cancer cell lines were infected with
HAdV-C5 (black squares), HAdV-D9 (white squares) or HAdVD51 (black diamonds) at indicated MOIs. Cell survival in each
well was measured at 6 days post-infection using MTS assay and
plotted on y-axis as the percentage of the control values obtained
from uninfected cells. Data points represent mean + standard error
of the mean (n = 3).
(TIF)
Table S1 Genome copy numbers of HAdVs at an
absorbance of 1.0 at 260 nm.
(DOC)
Table

S2 Classification

and cellular receptors of

HAdVs.
(DOC)

Acknowledgments
Supporting Information

We thank Drs. Barbara Muz and Jesse J. Parry for flow cytometry analysis.

Figure S1 Standard curves of the HAdV-C5 and D9
genomes for qPCR. The copy numbers of purified HAdV
genomes was calculated as described in the Materials and Methods
section. A 100-fold serial dilution of purified HAdV genomes
ranging from 102 to 108 copies per reaction was used to generate

Author Contributions
Conceived and designed the experiments: HU. Performed the experiments:
JU HU. Analyzed the data: JU HU. Contributed reagents/materials/
analysis tools: HU DTC. Wrote the paper: JU HU.

References
8. Shenk TE (2001) Adenoviridae: the viruses and their replication; Knipe DM,
Howley PM, editors. Philadelphia: Lippincott Williams & Wilkins. 1053–1088 p.
9. Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A (2004) Transductional
and transcriptional targeting of adenovirus for clinical applications. Current
gene therapy 4: 1–14.
10. Ugai H, Dobbins GC, Wang M, Le LP, Matthews DA, et al. (2012) Adenoviral
protein V promotes a process of viral assembly through nucleophosmin 1.
Virology 432: 283–295.
11. Ramirez PJ, Vickers SM, Ono HA, Davydova J, Takayama K, et al. (2008)
Optimization of conditionally replicative adenovirus for pancreatic cancer and
its evaluation in an orthotopic murine xenograft model. Am J Surg 195: 481–
490.
12. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:
658–670.

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer
journal for clinicians 62: 10–29.
2. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to
organ-specific colonization. Nature reviews Cancer 9: 274–284.
3. McCormick F (2001) Cancer gene therapy: fringe or cutting edge? Nature
reviews Cancer 1: 130–141.
4. Chiocca EA (2002) Oncolytic viruses. Nature reviews Cancer 2: 938–950.
5. Russell SJ, Peng KW (2007) Viruses as anticancer drugs. Trends in
pharmacological sciences 28: 326–333.
6. Curiel DT (2000) The development of conditionally replicative adenoviruses for
cancer therapy. Clinical cancer research 6: 3395–3399.
7. Alemany R, Balague C, Curiel DT (2000) Replicative adenoviruses for cancer
therapy. Nature biotechnology 18: 723–727.

PLOS ONE | www.plosone.org

9

February 2014 | Volume 9 | Issue 2 | e87342

Human Adenovirus 9 Has Better Virus-Spread Ability

13. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, et al. (2009) An
acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice
and permissive Syrian hamsters; comparisons with wild-type Ad5 and a
replication-defective adenovirus vector. Cancer gene therapy 16: 644–654.
14. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, et al. (2008) Directed
evolution generates a novel oncolytic virus for the treatment of colon cancer.
PLoS One 3: e2409.
15. Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, et al. (2013) A
phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with
recurrent ovarian cancer. Gynecol Oncol.
16. Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, et al. (2009) A phase I trial of
intratumoral administration of recombinant oncolytic adenovirus overexpressing
HSP70 in advanced solid tumor patients. Gene Ther 16: 376–382.
17. Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, et al. (2010)
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid
tumors. Clin Cancer Res 16: 3035–3043.
18. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, et al. (2010)
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus
expressing GMCSF. Mol Ther 18: 1874–1884.
19. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, et al. (2010)
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating
factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297–
4309.
20. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, et al. (2010) A
phase I study of telomerase-specific replication competent oncolytic adenovirus
(telomelysin) for various solid tumors. Molecular therapy: the journal of the
American Society of Gene Therapy 18: 429–434.
21. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, et al. (2002) Phase I
study of replication-competent adenovirus-mediated double suicide gene therapy
for the treatment of locally recurrent prostate cancer. Cancer research 62: 4968–
4976.
22. Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, et al. (2010) A phase
I study of a tropism-modified conditionally replicative adenovirus for recurrent
malignant gynecologic diseases. Clinical cancer research 16: 5277–5287.
23. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, et al. (2006) CG0070, a
conditionally replicating granulocyte macrophage colony-stimulating factor–
armed oncolytic adenovirus for the treatment of bladder cancer. Clinical cancer
research 12: 305–313.
24. Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replicationselective adenovirus for the treatment of cancer: what have we learned? Gene
therapy 8: 89–98.
25. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, et al. (2001) Wild-type
adenovirus decreases tumor xenograft growth, but despite viral persistence
complete tumor responses are rarely achieved–deletion of the viral E1b-19-kD
gene increases the viral oncolytic effect. Human Gene Therapy 12: 1323–1332.
26. Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, et al. (2003) Intratumoral
spread of wild-type adenovirus is limited after local injection of human xenograft
tumors: virus persists and spreads systemically at late time points. Human Gene
Therapy 14: 425–433.
27. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, et al. (2007)
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic
adenovirus based on the pRB pathway. Molecular therapy: the journal of the
American Society of Gene Therapy 15: 1607–1615.
28. Sauthoff H, Heitner S, Rom WN, Hay JG (2000) Deletion of the adenoviral
E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector.
Human Gene Therapy 11: 379–388.
29. Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, et al. (2001) A
midkine promoter-based conditionally replicative adenovirus for treatment of
pediatric solid tumors and bone marrow tumor purging. Cancer research 61:
7882–7888.
30. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT (2001)
Characterization of the cyclooxygenase-2 promoter in an adenoviral vector
and its application for the mitigation of toxicity in suicide gene therapy of
gastrointestinal cancers. Molecular therapy: the journal of the American Society
of Gene Therapy 3: 385–394.
31. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, et al. (2001) A phase I
trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for
the treatment of locally recurrent prostate cancer following radiation therapy.
Cancer research 61: 7464–7472.
32. Glasgow JN, Everts M, Curiel DT (2006) Transductional targeting of adenovirus
vectors for gene therapy. Cancer gene therapy 13: 830–844.
33. Beatty MS, Curiel DT (2012) Chapter two–Adenovirus strategies for tissuespecific targeting. Advances in cancer research 115: 39–67.
34. Chen CY, Weaver EA, Khare R, May SM, Barry MA (2011) Mining the
adenovirus virome for oncolytics against multiple solid tumor types. Cancer gene
therapy 18: 744–750.
35. Subramanian T, Vijayalingam S, Chinnadurai G (2006) Genetic identification
of adenovirus type 5 genes that influence viral spread. J Virol 80: 2000–2012.
36. Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, et al. (2003)
Developing novel oncolytic adenoviruses through bioselection. J Virol 77: 2640–
2650.
37. Fields BN, Knipe DM, Howley PM (2007) Fields virology. Philadelphia: Wolters
Kluwer Health/Lippincott Williams & Wilkins.

PLOS ONE | www.plosone.org

38. Green M, Pina M, Kimes RC (1967) Biochemical studies on adenovirus
multiplication. XII. Plaquing efficiencies of purified human adenoviruses.
Virology 31: 562–565.
39. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al.
(1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses
2 and 5. Science 275: 1320–1323.
40. Kanegae Y, Makimura M, Saito I (1994) A simple and efficient method for
purification of infectious recombinant adenovirus. Japanese journal of medical
science & biology 47: 157–166.
41. Ugai H, Suzuki E, Inabe K, Murata T, Hamada H, et al. (2003) Spontaneous
mutations in the human gene for p53 in recombinant adenovirus during multiple
passages in human embryonic kidney 293 cells. Biochem Biophys Res Commun
300: 448–456.
42. Maizel JV Jr, White DO, Scharff MD (1968) The polypeptides of adenovirus. I.
Evidence for multiple protein components in the virion and a comparison of
types 2, 7A, and 12. Virology 36: 115–125.
43. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning, a laboratory
manual. NY: Cold Spring Harbor Laboratory Press.
44. Ugai H, Wang M, Le LP, Matthews DA, Yamamoto M, et al. (2010) In vitro
dynamic visualization analysis of fluorescently labeled minor capsid protein IX
and core protein V by simultaneous detection. J Mol Biol 395: 55–78.
45. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT (1996) Generation of
recombinant adenovirus vectors with modified fibers for altering viral tropism.
J Virol 70: 6839–6846.
46. Saito I, Oya Y, Yamamoto K, Yuasa T, Shimojo H (1985) Construction of
nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA
near the right end of its genome. J Virol 54: 711–719.
47. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL (1988) A monoclonal
antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol
62: 1647–1652.
48. Kim M, Sumerel LA, Belousova N, Lyons GR, Carey DE, et al. (2003) The
coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant
glioma cells. Br J Cancer 88: 1411–1416.
49. Murakami M, Ugai H, Belousova N, Pereboev A, Dent P, et al. (2010) Chimeric
adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently
mediate gene transfer into prostate cancer cells. The Prostate 70: 362–376.
50. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, et al. (2008)
Bioselection of a gain of function mutation that enhances adenovirus 5 release
and improves its antitumoral potency. Cancer research 68: 8928–8937.
51. Ugai H, Borovjagin AV, Le LP, Wang M, Curiel DT (2007) Thermostability/
infectivity defect caused by deletion of the core protein V gene in human
adenovirus type 5 is rescued by thermo-selectable mutations in the core protein
X precursor. J Mol Biol 366: 1142–1160.
52. Arnberg N (2009) Adenovirus receptors: implications for tropism, treatment and
targeting. Reviews in medical virology 19: 165–178.
53. Zhang Y, Bergelson JM (2005) Adenovirus receptors. J Virol 79: 12125–12131.
54. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, et al. (1998) The
coxsackievirus-adenovirus receptor protein can function as a cellular attachment
protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72:
7909–7915.
55. Kirby I, Lord R, Davison E, Wickham TJ, Roelvink PW, et al. (2001)
Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor
(CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus
serotypes. J Virol 75: 7210–7214.
56. Roelvink PW, Kovesdi I, Wickham TJ (1996) Comparative analysis of
adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the
same cellular fiber receptor but use different binding strategies for attachment.
J Virol 70: 7614–7621.
57. Tang Y, Wu H, Ugai H, Matthews QL, Curiel DT (2009) Derivation of a triple
mosaic adenovirus for cancer gene therapy. PLoS One 4: e8526.
58. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL (1988) A monoclonal
antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol
62: 1647–1652.
59. Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, et al.
(2002) Exploiting the natural diversity in adenovirus tropism for therapy and
prevention of disease. J Virol 76: 4612–4620.
60. Prage L, Hoglund S, Philipson L (1972) Structural proteins of adenoviruses. 8.
Characterization of incomplete particles of adenovirus type 3. Virology 49: 745–
757.
61. Tiemessen CT, Kidd AH (1994) Adenovirus type 40 and 41 growth in vitro:
host range diversity reflected by differences in patterns of DNA replication.
J Virol 68: 1239–1244.
62. Yamasaki S, Miura Y, Brown E, Davydova J, Yamamoto M (2010)
Development of a method for effective amplification of human adenovirus 40.
Arch Virol 155: 1059–1068.
63. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, et al. (2003)
Replication-deficient human adenovirus type 35 vectors for gene transfer and
vaccination: efficient human cell infection and bypass of preexisting adenovirus
immunity. J Virol 77: 8263–8271.
64. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, et al. (2011)
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass
immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
J Virol 85: 4222–4233.

10

February 2014 | Volume 9 | Issue 2 | e87342

Human Adenovirus 9 Has Better Virus-Spread Ability

65. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007)
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654–
4663.
66. Kibrick S, Melendez L, Enders JF (1957) Clinical associations of enteric viruses
with particular reference to agents exhibiting properties of the ECHO group.
Ann N Y Acad Sci 67: 311–325.
67. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, Slaterus KW,
Wertheim-Van Dillen P, et al. (1999) Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new
candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin
Microbiol 37: 3940–3945.
68. Dey SK, Shimizu H, Phan TG, Hayakawa Y, Islam A, et al. (2009) Molecular
epidemiology of adenovirus infection among infants and children with acute
gastroenteritis in Dhaka City, Bangladesh. Infect Genet Evol 9: 518–522.
69. Liu EB, Wadford DA, Seto J, Vu M, Hudson NR, et al. (2012) Computational
and serologic analysis of novel and known viruses in species human adenovirus
D in which serology and genomics do not correlate. PLoS One 7: e33212.
70. Kemp MC, Hierholzer JC, Cabradilla CP, Obijeski JF (1983) The changing
etiology of epidemic keratoconjunctivitis: antigenic and restriction enzyme
analyses of adenovirus types 19 and 37 isolated over a 10-year period. The
Journal of infectious diseases 148: 24–33.
71. Ford E, Nelson KE, Warren D (1987) Epidemiology of epidemic keratoconjunctivitis. Epidemiologic reviews 9: 244–261.
72. Blusch JH, Deryckere F, Windheim M, Ruzsics Z, Arnberg N, et al. (2002) The
novel early region 3 protein E3/49K is specifically expressed by adenoviruses of
subgenus D: implications for epidemic keratoconjunctivitis and adenovirus
evolution. Virology 296: 94–106.
73. Hierholzer JC (1992) Adenoviruses in the immunocompromised host. Clin
Microbiol Rev 5: 262–274.
74. Khoo SH, Bailey AS, de Jong JC, Mandal BK (1995) Adenovirus infections in
human immunodeficiency virus-positive patients: clinical features and molecular
epidemiology. J Infect Dis 172: 629–637.
75. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, Slaterus KW,
Wertheim-Van Dillen P, et al. (1999) Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new
candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin
Microbiol 37: 3940–3945.
76. Arnberg N, Edlund K, Kidd AH, Wadell G (2000) Adenovirus type 37 uses sialic
acid as a cellular receptor. J Virol 74: 42–48.
77. Arnberg N, Kidd AH, Edlund K, Olfat F, Wadell G (2000) Initial interactions of
subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v)
integrins. J Virol 74: 7691–7693.

PLOS ONE | www.plosone.org

78. Arnberg N, Kidd AH, Edlund K, Nilsson J, Pring-Akerblom P, et al. (2002)
Adenovirus type 37 binds to cell surface sialic acid through a charge-dependent
interaction. Virology 302: 33–43.
79. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for
group B adenoviruses. Nature medicine 9: 1408–1412.
80. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H (2000) Dependence of
efficient adenoviral gene delivery in malignant glioma cells on the expression
levels of the Coxsackievirus and adenovirus receptor. Journal of neurosurgery
92: 1002–1008.
81. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, et al. (1999) Loss of
adenoviral receptor expression in human bladder cancer cells: a potential impact
on the efficacy of gene therapy. Cancer research 59: 325–330.
82. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, et al.
(2002) Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical
bladder cancer. Urology 60: 531–536.
83. Anders M, Vieth M, Rocken C, Ebert M, Pross M, et al. (2009) Loss of the
coxsackie and adenovirus receptor contributes to gastric cancer progression.
Br J Cancer 100: 352–359.
84. Auer D, Reimer D, Porto V, Fleischer M, Roessler J, et al. (2009) Expression of
coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
Breast cancer research and treatment 116: 103–111.
85. Korn WM, Macal M, Christian C, Lacher MD, McMillan A, et al. (2006)
Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal
cancer correlates with tumor differentiation. Cancer gene therapy 13: 792–797.
86. Matsumoto K, Shariat SF, Ayala GE, Rauen KA, Lerner SP (2005) Loss of
coxsackie and adenovirus receptor expression is associated with features of
aggressive bladder cancer. Urology 66: 441–446.
87. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, et al. (2001) The
mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor
(CAR) on human bladder cancer: a functional analysis of car protein structure.
Cancer research 61: 6592–6600.
88. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, et al. (2002) Expression of
the coxsackie adenovirus receptor in normal prostate and in primary and
metastatic prostate carcinoma: potential relevance to gene therapy. Cancer
research 62: 3812–3818.
89. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, et al. (2002)
Determination of molecules regulating gene delivery using adenoviral vectors in
ovarian carcinomas. Gene therapy 9: 1093–1100.
90. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008)
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397–409.
91. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, et al. (2008)
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.
Proceedings of the National Academy of Sciences of the United States of
America 105: 5483–5488.

11

February 2014 | Volume 9 | Issue 2 | e87342

